Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Thomas Tuschl
New York University School of Medicine, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Regulus Therapeutics Inc
Reimbursed or sponsored travel
This grant project could provide Regulus information about novel biomarkers used for diagnosis of diseases. Regulus’ company strategy includes identifying microRNA biomarkers.
Multi-Ethnic Translational Research Optimization (METRO) Lupus Consortium
The Multi-Ethnic Translational Research Optimization (METRO) Lupus Consortium will enroll and follow approximately 300 patients who have systemic lupus erythematosus (SLE). The causes of this potentially fatal, heterogeneous, chronic, and systemic autoimmune disease are not well understood, but its incidence, prevalence and severity are known to be affected by race and ethnicity, as well as socioeconomic status. Our proposed studies will focus on identification of treatable targets specific to kidney injury, and in particular to assess whether similar targets can be identified in cells from the skin, blood or urine which may help to predict kidney disease less invasively and at an earlier stage; the goal is to begin treatment of kidney disease much earlier than is now possible, and ultimately preserve kidney function in patients with SLE.
Filed on December 08, 2014.
Tell us what you know about Thomas Tuschl's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Thomas Tuschl filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Thomas Tuschl | New York University School of Medicine | Conflict of Interest | Regulus Therapeutics Inc | $200,000 - $249,999 |
| Thomas Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $40,000 - $59,999 |
| Thomas Tuschl | New York University School of Medicine | Conflict of Interest | Regulus Therapeutics Inc | $20,000 - $39,999 |
| Thomas Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $20,000 - $39,999 |
| Thomas Tuschl | New York University School of Medicine | Conflict of Interest | Max Planck Institute | $10,000 - $19,999 |
| Thomas Tuschl | Rockefeller University | Conflict of Interest | Max Planck | $10,000 - $19,999 |
| Thomas Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.